Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Genitourinary 2CNS 2Thoracic 1Other hematologic neoplasm 1Dermatologic 1Breast 1

Conditions

Glioblastoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 123Radiotherapy 47Bevacizumab 46Lomustine 25Radiation 20Nivolumab 17Irinotecan 16Carboplatin 16Cyclophosphamide 14Granulocyte-Macrophage Colony-Stimulating Factor 13pembrolizumab 11dabrafenib 10Trastuzumab 10Surgical Procedures, Operative 10Capecitabine 10paclitaxel-Angiopep-2 conjugate 8TIC10 compound 8Paclitaxel 8Gemcitabine 8Carmustine 8trametinib 7Topotecan 7IL13-PE38 7Everolimus 7Drug Therapy 7Aminolevulinic Acid 7AZD 6244 73-Iodobenzylguanidine 7fludarabine 6enzastaurin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × infigratinib × CNS × Clear all
NCT05222165 2023-02-23

NEWEL

Helsinn Healthcare SA

Phase 1/2 Withdrawn
CNS

Central Nervous System Neoplasms

NCT01975701 2019-12-04

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Novartis

Phase 2 Completed
26 enrolled 10 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡